8.735  1.325 (17.88%)		10-09 15:45
Open: 7.57 High: 8.83 Volume: 938,317		Pre. Close: 7.41 Low: 7.47 Market Cap: 447(M)

Short term
Mid term
Targets	6-month :	9.78	1-year :	11.43
Resists	First :	8.38	Second :	9.78
Pivot price	7.16
Supports	First :	6.17	Second :	4.81
MAs	MA(5) :	7.6	MA(20) :	6.93
	MA(100) :	4.51	MA(250) :	5.6
MACD	MACD :	0.6	Signal :	0.6
%K %D	K(14,3) :	65.5	D(3) :	61.8
RSI	RSI(14): 69.3
52-week	High :	11	Low :	2.65

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ENGN ] has closed below upper band by 1.6%. Bollinger Bands are 68% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	7.49 - 7.54	7.54 - 7.58
Low:	6.96 - 7.01	7.01 - 7.06
Close:	7.33 - 7.41	7.41 - 7.48

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Thu, 09 Oct 2025
Will EnGene Join The Ranks Of Merck, Ferring, And ImmunityBio In Bladder Cancer Treatment? - RTTNews

Thu, 02 Oct 2025
enGene Holdings Inc. (NASDAQ:ENGN) Sees Large Growth in Short Interest - MarketBeat

Thu, 02 Oct 2025
enGene Holdings amends executive employment agreement to increase CIC payout - Investing.com

Thu, 02 Oct 2025
enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Wed, 01 Oct 2025
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - businesswire.com

Wed, 01 Oct 2025
enGene Holdings Appoints New Chief Medical Officer - The Globe and Mail

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	51 (M)
Shares Float	19 (M)
Held by Insiders	13.6 (%)
Held by Institutions	89.5 (%)
Shares Short	45 (K)
Shares Short P.Month	5 (K)

EPS	-1.9
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.93
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-24.7 %
Return on Equity (ttm)	-44 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.98
Qtrly Earnings Growth	0 %
Operating Cash Flow	-94 (M)
Levered Free Cash Flow	-60 (M)

PE Ratio	-4.36
PEG Ratio	0
Price to Book value	2.1
Price to Sales	0
Price to Cash Flow	-4.52

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.